Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Acta Biomater. 2020 Mar 7;108:111–127. doi: 10.1016/j.actbio.2020.03.007

Figure 2.

Figure 2.

Assessment of induction of an otic neuronal lineage from late-stage ONPs. (A): A stepwise treatment for an otic neuronal lineage induction. On day 25, PODS®-hBDNF treatment was started in NIM for 7 days. D: days. (B): Phase-contrast photomicrographs of hESC-derived late-stage ONPs. (C): Phase-contrast photomicrographs of hESC-derived ONPs treated with PODS®-hBDNF for seven days. (D–I): Immunocytochemistry of hESC-derived late-stage ONPs treated with PODS®-hBDNF in NIM/Brainphys™ shows expression of various otic neuronal markers: GATA3, NEUROG1, PAX8, SOX2, nestin, VGLUT2, β-III tubulin, and peripherin. (J): Quantification of the otic neuronal markers for % positivity (n = 3) on hESC-derived late-stage ONPs treated with PODS®-hBDNF for seven days. BT: β-III tubulin; GT3: GATA3; N: nestin; NG1: neurogenin 1; P8: PAX8; PRN: peripherin; S2: SOX2; and VG2: VGLUT2. (K): Quantification of % positive staining for nestin, PAX8, and SOX2 on PODS®-hBDNF and RhBDNF treated cells. *p <0.05, ** p < 0.01 by one-way ANOVA with Tukey’s post-hoc test. n.s.: not statistically significant.